THL Credit TCRX 深 沪
等待开盘 08-26 09:30:00 美东时间
1.88
+0.010
+0.53%
华盛通- 最 高1.93
- 今 开1.90
- 成交量 14.02万股
- 最 低 1.80
- 昨 收 1.87
- 总市值 1.07亿
- 52周最高 6.225
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.02
- 委 比 56.37%
- 总股本 5674.80万
- 历史最高 14.71
- 量 比 0.66
- 振 幅 6.95%
- 历史最低 1.02
- 每 手 1
- 风险率 1.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TScan Therapeutics Q2 EPS $(0.28), Inline, Sales $3.076M Beat $1.405M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $3.076
08-12 19:12
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics reported Q2 2025 financial results, including revenue of $3.1 million, R&D expenses of $32.6 million, and a net loss of $37.0 million. The company announced plans to treat first solid tumor patients with multiplex TCR-T therapy in Q3 2025 and expects to present two-year relapse data from the ALLOHA™ Phase 1 trial by year-end. Cash reserves of $218 million are sufficient to fund operations into Q1 2027.
08-12 11:00
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics, Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 4:55 p.m. ET in New York. A webcast will be available on the company’s website, ir.tscan.com, with an archived replay for 90 days. TScan is a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment. The company is currently enrolling patients in two clinical programs: ALLOHA™ for hematologic malignancies a...
05-28 11:00
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.
05-07 20:26
TScan Therapeutics GAAP EPS of $0.26
TScan Therapeutics press release (NASDAQ:TCRX): Q1 GAAP EPS of $0.26. Revenue of $2.2M beats by $1.12M. More on TScan Therapeutics TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 TScan Ther...
05-06 23:13
美股大行评级 | 潜在涨幅147.43%！HC Wainwright & Co.上调Pacira BioSciences目标价至65美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116650478822592513.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Pacira BioSciences(PCRX)"买入"评级，目标价从48美元升至65美元</p> <p>• 瑞穗：上调Amylyx Pharmaceuticals(AM
04-09 08:50
Needham Reiterates Buy on TScan Therapeutics, Maintains $9 Price Target
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9 price target.
04-08 20:46
美股大行评级 | 美银证券：维持AerCap Holdings"买入"评级，目标价从105美元升至125美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1105190809351499777.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Canadian Natural Res(CNQ)"跑赢大市"评级，目标价从62美元升至63美元</p> <p>• 摩根大通：维持Carvana(CVNA)"超配"评级，目标价从350美元升至3
03-10 10:29
美股大行评级 | 摩根大通：维持Alignment Healthcare"中性"评级，目标价从14美元升至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104689832132448256.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Chardan Capital：维持Ocugen(OCGN)"买入"评级，目标价从6美元升至7美元</p> <p>• Piper Sandler：维持ALX Oncology Holdings(ALXO)"超配"评级，目标
03-07 13:53
